Related Experiment Video
Updated: Aug 5, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Reprogramming Inflammatory Macrophages with Specialized Pro-Resolving Lipid Mediators: A Novel Immunotherapeutic
Ruchita Tanu1, Ashraf A Qurtam2, Gagan Prakash1
1Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur 303002, Rajasthan, India.
Biomedicines
|July 28, 2026
Summary
Specialized pro-resolving mediators (SPMs) reprogram macrophages to actively resolve asthma inflammation, offering a novel therapeutic approach. These potent lipid mediators promote healing and immune balance, unlike current suppressive treatments.
Area of Science:
- Immunology
- Pharmacology
- Respiratory Medicine
Background:
- Asthma is a chronic inflammatory airway disorder characterized by immune over-activation and impaired inflammation resolution.
- Specialized pro-resolving mediators (SPMs) are crucial for maintaining immune homeostasis and macrophage plasticity.
- Current asthma therapies primarily focus on suppressing inflammation, often neglecting active resolution pathways.
Purpose of the Study:
- To review the therapeutic potential of SPM-programmed macrophage reprogramming for asthma.
- To explore how SPMs actively promote inflammation resolution, contrasting with current anti-inflammatory strategies.
- To discuss the preclinical evidence and future challenges for SPM-based asthma therapies.
Main Methods:
- Review of preclinical studies on SPM functions in experimental asthma models.
- Analysis of SPM subclasses in asthmatic patients to identify defective resolution pathways.
- Examination of mechanisms underlying SPM-mediated resolution, including cytokine modulation and macrophage phenotype alteration.
Main Results:
- SPMs (lipoxins, resolvins, protectins, maresins) alleviate asthma symptoms and airway hyperresponsiveness in animal models.
- Reduced SPM levels in severe asthmatics suggest defective resolution pathways contribute to disease persistence.
- SPMs facilitate resolution by down-regulating pro-inflammatory cytokines and promoting pro-resolving macrophage phenotypes.
Conclusions:
- SPM-programmed macrophage reprogramming represents a promising novel therapeutic strategy for asthma.
- Development of stable SPM analogs and targeted delivery systems enhances their therapeutic potential.
- Personalized, resolution-based therapies using multi-omics and biomarkers are envisioned for steroid-resistant and non-type 2 asthma, pending further clinical validation.
Related Concept Videos
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:38Inflammation
Overview